Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome.
about
The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to manNew pharmacological strategies in rheumatic diseasesAdvances in salivary gland gene therapy - oral and systemic implicationsInhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice.Childhood Sjögren syndrome: insights from adults and animal modelsImmune checkpoint receptors in regulating immune reactivity in rheumatic disease.Matriptase deletion initiates a Sjögren's syndrome-like disease in mice.Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-InteMouse Models of Primary Sjogren's Syndrome.IL-17 sequestration via salivary gland gene therapy in a mouse model of Sjogren's syndrome suppresses disease-associated expression of the putative autoantigen Klk1b22Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren's syndrome and in miceDysregulated co-stimulatory molecule expression in a Sjögren's syndrome mouse model with potential implications by microRNA-146aSmad4 in T cells plays a protective role in the development of autoimmune Sjögren's syndrome in the nonobese diabetic mouse.Neutralizing antibodies against adeno-associated viruses in Sjögren's patients: implications for gene therapy.Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study.
P2860
Q26825196-67EF95E2-A615-410A-97BE-BF9908593D2DQ28073763-02163616-361E-48CC-BB2A-59D0DB83A037Q28084318-A44CF371-C0C0-4653-80AB-72311ABFDE5CQ33688996-A2D59FF5-EAE8-44CC-ACF0-33A8E8738FF1Q33724868-A38EC6EB-A8C3-4A92-88FC-25ACF6D41A88Q34897654-BF97642C-90AD-4962-BFC1-1086F7AD6989Q35097182-E0C9E7F9-52DE-4EF3-8693-56977AD3C57AQ35318424-CDEE809C-1F62-4BBA-9D28-0A2E66DC1860Q35587450-A003BA5A-C076-4F85-8F6D-95C7F269105FQ35923212-46A186C5-6F3D-4999-8509-B74A85F541C0Q35923627-C4AF6057-9326-4D99-A013-AEB3374C836DQ36373330-6D7121F6-E97C-4157-AA5E-361D5F356DD7Q37696996-61AD3CA0-CB45-4571-BFBA-51263D4B3F7CQ40354609-88C0F405-1E39-43E0-9DE5-36D73DB49330Q44697565-076FBEE2-5379-4377-A131-43965CF06F7E
P2860
Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Local delivery of AAV2-CTLA4Ig ...... e model of Sjögren's syndrome.
@ast
Local delivery of AAV2-CTLA4Ig ...... e model of Sjögren's syndrome.
@en
type
label
Local delivery of AAV2-CTLA4Ig ...... e model of Sjögren's syndrome.
@ast
Local delivery of AAV2-CTLA4Ig ...... e model of Sjögren's syndrome.
@en
prefLabel
Local delivery of AAV2-CTLA4Ig ...... e model of Sjögren's syndrome.
@ast
Local delivery of AAV2-CTLA4Ig ...... e model of Sjögren's syndrome.
@en
P2093
P2860
P356
P1476
Local delivery of AAV2-CTLA4Ig ...... e model of Sjögren's syndrome.
@en
P2093
Ammon B Peck
Cuong Q Nguyen
Hongen Yin
John A Chiorini
Toshimitsu Uede
Yuval Samuni
P2860
P2888
P356
10.1186/AR3753
P577
2012-02-27T00:00:00Z
P5875
P6179
1050935954